HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joan M Carboni Selected Research

BMS 536924

9/2012IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein.
12/2011IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
2/2011ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway.
1/2011Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
11/2010Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
1/2010Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes.
11/2009BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
10/2009Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
1/2009The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
1/2009BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joan M Carboni Research Topics

Disease

18Neoplasms (Cancer)
03/2012 - 01/2005
9Breast Neoplasms (Breast Cancer)
03/2012 - 09/2008
4Rhabdomyosarcoma
11/2010 - 01/2009
3Neoplasm Metastasis (Metastasis)
03/2012 - 01/2006
3Sarcoma (Soft Tissue Sarcoma)
11/2010 - 01/2009
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
09/2012 - 10/2009
2Leukemia
09/2012 - 12/2009
2Neuroblastoma
12/2009 - 01/2009
2Carcinogenesis
05/2005 - 01/2005
1Colorectal Neoplasms (Colorectal Cancer)
02/2015
1Prostatic Neoplasms (Prostate Cancer)
01/2012
1Hyperinsulinism (Hyperinsulinemia)
12/2011
1Hyperglycemia
12/2011
1Triple Negative Breast Neoplasms
04/2011
1Resistance To Insulin-Like Growth Factor I
09/2010
1Carcinoid Tumor (Carcinoid)
09/2010
1Hypersensitivity (Allergy)
09/2010
1Type 2 Diabetes Mellitus (MODY)
01/2010
1Multiple Myeloma
12/2009
1Liposarcoma
12/2009
1Ovarian Epithelial Carcinoma
11/2009
1Osteosarcoma (Osteogenic Sarcoma)
03/2009
1Ewing Sarcoma (Sarcoma, Ewing)
01/2009
1Ovarian Neoplasms (Ovarian Cancer)
09/2008
1T-Cell Leukemia (Leukemia, T Cell)
01/2006
1Adenocarcinoma
05/2005

Drug/Important Bio-Agent (IBA)

11BMS 536924IBA
09/2012 - 09/2008
9Insulin ReceptorIBA
09/2012 - 01/2006
7BMS 754807IBA
02/2015 - 12/2009
7Phosphotransferases (Kinase)IBA
09/2012 - 05/2005
6Tyrosine Kinase InhibitorsIBA
09/2012 - 01/2009
5Insulin (Novolin)FDA Link
01/2012 - 10/2009
5IGF Type 1 Receptor (IGF 1 Receptor)IBA
02/2011 - 05/2005
4Insulin-Like PeptidesIBA
12/2011 - 01/2011
4Insulin-Like Growth Factor I (IGF-1)IBA
04/2011 - 05/2005
3Biomarkers (Surrogate Marker)IBA
02/2015 - 01/2009
3Proteins (Proteins, Gene)FDA Link
03/2012 - 01/2005
3Pharmaceutical PreparationsIBA
12/2011 - 11/2010
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
12/2011 - 11/2010
3AntibodiesIBA
04/2011 - 09/2010
3Somatomedin Receptors (Somatomedin Receptor)IBA
01/2011 - 01/2006
3Protein Isoforms (Isoforms)IBA
09/2010 - 03/2009
2BMS-554417IBA
09/2008 - 01/2006
1Cre recombinaseIBA
09/2012
1Tyrosine (L-Tyrosine)FDA Link
09/2012
1Insulin-Like Growth Factor Binding Protein 4IBA
03/2012
1Insulin-Like Growth Factor Binding ProteinsIBA
03/2012
1Insulin-Like Growth Factor Binding Protein 5IBA
03/2012
1Dasatinib (BMS 354825)FDA Link
01/2012
1src-Family KinasesIBA
01/2012
1Letrozole (Femara)FDA LinkGeneric
12/2011
1Hormones (Hormone)IBA
12/2011
1Estrogens (Estrogen)FDA Link
12/2011
1Antineoplastic Agents (Antineoplastics)IBA
12/2011
1TamoxifenFDA LinkGeneric
12/2011
1Metformin (Glucophage)FDA LinkGeneric
12/2011
1AlloxanIBA
12/2011
1Docetaxel (Taxotere)FDA Link
04/2011
1Phenobarbital (Luminal)FDA Link
02/2011
1matrigelIBA
02/2011
1benzimidazoleIBA
01/2011
1Ribosomal Protein S6IBA
11/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2010
1Small Interfering RNA (siRNA)IBA
11/2010
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
09/2010
1Transforming Growth Factor-beta Type I ReceptorIBA
09/2010
1Glucose (Dextrose)FDA LinkGeneric
01/2010
14- chloro- 3',6'- dimethyl- 2,2'- iminodibenzoate (TO 115)IBA
12/2009
1Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
12/2009
1Caspase 3 (Caspase-3)IBA
12/2009
1Poly(ADP-ribose) Polymerase InhibitorsIBA
11/2009
13-aminobenzamideIBA
11/2009
1Insulin-Like Growth Factor II (Somatomedin A)IBA
03/2009
1(4- ((1- (3- fluorophenyl)methyl)- 1H- indazol- 5- ylamino)- 5- methylpyrrolo(2,1- f)(1,2,4)triazin- 6- yl)carbamic acid 3-morpholinylmethyl esterIBA
09/2008
1Cyclin D1IBA
01/2006
1LR(3)IGF-IIBA
01/2006
1AS 8IBA
05/2005
1Ornithine Decarboxylase (Decarboxylase, Ornithine)IBA
01/2005
1Keratin-14 (Keratin 14)IBA
01/2005
1Drinking WaterIBA
01/2005
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2005
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
01/2005
1Eflornithine (Ornidyl)FDA Link
01/2005

Therapy/Procedure

9Therapeutics
12/2011 - 09/2008
1Bone Marrow Transplantation (Transplantation, Bone Marrow)
09/2012
1Mammaplasty (Breast Reconstruction)
03/2012